Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0101)
| Name |
Sodium butyrate
|
||||
|---|---|---|---|---|---|
| Synonyms |
SODIUM BUTYRATE; 156-54-7; Sodium butanoate; Butyric acid sodium salt; Butanoic acid, sodium salt; Butyric acid, sodium salt; Butyrate sodium; sodium;butanoate; Sodium n-butyrate; Sodium propanecarboxylate; Butanoic acid sodium salt; Butyric Acid, Na; C4H7NaO2; Sodium butyrate (USP); Sodium butyrate [USP]; TPA/BA; Butanoic acid, sodium salt (1:1); 8RAS91C36W; DTXSID3037672; CHEBI:64103; NSC-174280; CHEMBL62381; CCRIS 7068; NSC174280; HSDB 5655; SODIUM BUTYRATE-3,3,4,4,4-D5; NCGC00167555-01; EINECS 205-857-6; MFCD00002816; NSC 174280; sodiumbutyrate; UNII-8RAS91C36W; 204244-79-1; Sodium butyrate, 98%; Tetradecanoyl phorbol acetate/ sodium butyrate; SCHEMBL30148; SODIUM BUTYRATE [HSDB]; DTXCID1017672; HY-B0350A; SODIUM BUTYRATE [USP-RS]; SODIUM BUTYRATE [WHO-DD]; tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA); MFBOGIVSZKQAPD-UHFFFAOYSA-M; HMS3650B09; BCP31813; Butanoicacidsodiumsalt butyratesodium; Tox21_112550; HB1399; s1999; Sodium butyrate, >=98.5% (GC); Sodium butyrate, >=99.0% (GC); AKOS003051490; AKOS015899795; CCG-266046; CS-3924; SODIUM BUTYRATE [USP MONOGRAPH]; AS-13929; CAS-156-54-7; FT-0660356; FT-0694101; D08998; AB01274751-01; Sodium butyrate, Vetec(TM) reagent grade, 99%; A921858; Q305004; Sodium butyrate, certified reference material, TraceCERT(R); Sodium butyrate, United States Pharmacopeia (USP) Reference Standard
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C4H7NaO2
|
||||
| IUPAC Name |
sodium;butanoate
|
||||
| Canonical SMILES |
CCCC(=O)[O-].[Na+]
|
||||
| InChI |
InChI=1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1
|
||||
| InChIKey |
MFBOGIVSZKQAPD-UHFFFAOYSA-M
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Suppressor | ||||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | |||
| Responsed Regulator | CD44 antigen (CD44) | Suppressor | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Apoptosis | hsa04210 | ||||
| Cell Process | Cell ferroptosis | ||||
| Cell apoptosis | |||||
| Cell proliferation | |||||
| In Vitro Model | FHC cells | Normal | Homo sapiens | CVCL_3688 | |
| HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 | ||
| In Vivo Model |
Six-week-old male C57BL/6J mice were purchased from the Medical Laboratory Animal Center of Guangdong Province (Foshan, China). Forty-five C57BL/6L mice were randomized into 4 groups after 1 week of adaptive feeding: (1) Control group (n = 9); (2) AOM/DSS group (n = 12); (3) AOM/DSS + NaB (orally) group (n = 12); 4) AOM/DSS + NaB (intraperitoneal injection) group (n = 12). The Control group received an intraperitoneal injection of saline solution beginning on day 1, and received sterile drinking water throughout the study. Other three groups received an intraperitoneal injection of 10 mg/kg AOM (Sigma Aldrich) beginning on day 1, and received drinking water containing 2.5% DSS at the second and eighth weeks (2% DSS in the fifth week). Besides, 0.1 M NaB (Sigma Aldrich) was given in drinking water during the whole experiment process in AOM/DSS + NaB (p.o.) group, while AOM/DSS + NaB (i.p.) group was injected intraperitoneally (IP) with 1 g/kg NaB per day.
Click to Show/Hide
|
||||
| Response regulation | Sodium butyrate (NaB) induces ferroptosis in colorectal cancer cells through the CD44/SLC7A11 signaling pathway and has synergistic effects with Erastin. | ||||